DENALI THERAPEUTICS IN
29.60
07-November-24 15:59:55
15 minutes delayed
Stocks
+0.05
+0.17%
Today's range
29.02 - 31.41
ISIN
N/A
Source
NASDAQ
-
Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application
13 Jan 2022 08:00:01 By Nasdaq GlobeNewswire
-
10 Jan 2022 08:00:03 By Nasdaq GlobeNewswire
-
17 Nov 2021 08:30:00 By Nasdaq GlobeNewswire
-
Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
04 Nov 2021 16:01:00 By Nasdaq GlobeNewswire
-
06 Oct 2021 16:01:00 By Nasdaq GlobeNewswire
-
Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
27 Sep 2021 09:00:00 By Nasdaq GlobeNewswire
-
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
09 Sep 2021 09:00:01 By Nasdaq GlobeNewswire
-
Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
26 Aug 2021 11:00:00 By Nasdaq GlobeNewswire
-
25 Jul 2021 11:05:00 By Nasdaq GlobeNewswire
-
15 Jul 2021 09:00:01 By Nasdaq GlobeNewswire
-
28 Jun 2021 08:00:00 By Nasdaq GlobeNewswire
-
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
03 May 2021 08:30:00 By Nasdaq GlobeNewswire
-
11 Mar 2021 08:30:00 By Nasdaq GlobeNewswire
-
Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights
25 Feb 2021 16:01:01 By Nasdaq GlobeNewswire
-
12 Feb 2021 07:30:00 By Nasdaq GlobeNewswire
-
05 Feb 2021 09:00:00 By Nasdaq GlobeNewswire
-
Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors
11 Jan 2021 08:30:00 By Nasdaq GlobeNewswire
-
08 Jan 2021 08:30:00 By Nasdaq GlobeNewswire